Liver News and Research

RSS

Cells close to death from toxin exposure can survive when toxins are removed

The vast majority of cells that appear to be on a one-way track to death after exposure to toxins can bounce back completely after those toxins are removed, Johns Hopkins scientists report in a new study. The finding, published in the June 15 issue of Molecular Biology of the Cell, is not only a testament to the indomitable cellular spirit, but could also offer some practical insight on how to save dying tissues after heart attacks or strokes as well as prevent cancer in cells transiently exposed to toxins.

3 Jul 2012

DKK1 boosts liver cancer diagnostic options

Measurement of the protein Dickkopf-1 in serum could be used to diagnose hepatocellular carcinoma, especially early disease, Chinese researchers report.

2 Jul 2012

Procoagulant–fibrinolytic balance may predict hepatectomy thrombosis

An imbalance in procoagulant/fibrinolytic blood factors may point to an increased risk for thrombosis following liver surgery, research suggests.

2 Jul 2012

European collaboration to design a biomimetic bioartificial liver

Medicyte, The Electrospinning Company and the Universities of Manchester and Pisa launch a European wide unique project with the aim to design a biomimetic bioartificial liver (Re-Liver). The company GABO:mi ensures professional project management.

2 Jul 2012

3D printed templates of filament networks can improve function of engineered living tissues

Researchers are hopeful that new advances in tissue engineering and regenerative medicine could one day make a replacement liver from a patient's own cells, or animal muscle tissue that could be cut into steaks without ever being inside a cow.

2 Jul 2012

New volumetric functional MRI scan figures out beneficiaries of chemotherapy in liver cancer patients

Studies on some 55 U.S. men and women with potentially deadly liver or pancreatic cancers show that specialized MRI scans can tell within a month whether highly toxic chemotherapy is working and killing tumor cells long before tumors actually shrink - or fail to shrink.

2 Jul 2012

Under-performance of small bowel biopsy a major reason behind underdiagnosis of celiac disease

Under-performance of small bowel biopsy during endoscopy may be a major reason that celiac disease remains underdiagnosed in the United States, according to a new study published online recently in Gastrointestinal Endoscopy. Investigators at the Celiac Disease Center at Columbia University Medical Center (CUMC) found that the rate of small bowel biopsy is low in this country.

30 Jun 2012

New toxicology testing method requires lesser number of fish

A new way of testing the safety of natural and synthetic chemicals has been developed by scientists with funding from the Biotechnology and Biological Sciences Research Council (BBSRC). Their research, published today in the journal Ecotoxicology, could reduce the number of fish needed to test the toxicity of a range of chemicals including pharmaceuticals and environmental pollutants.

30 Jun 2012

Bees help understand connection between taste perception and metabolic syndromes

Scientists at Arizona State University have discovered that honey bees may teach us about basic connections between taste perception and metabolic disorders in humans. By experimenting with honey bee genetics, researchers have identified connections between sugar sensitivity, diabetic physiology and carbohydrate metabolism. Bees and humans may partially share these connections.

30 Jun 2012

CIHR and CH.I.L.D. create Canadian Children Inflammatory Bowel Disease Network

Dr. Grace McCarthy, Chairman of the Board of The Foundation for Children with Intestinal and Liver Disorders (CH.I.L.D), today announced an important new partnership with the Canadian Institutes of Health Research (CIHR) to fund the creation of the Canadian Children Inflammatory Bowel Disease Network: A Joint Partnership of CIHR and the CH.I.L.D. Foundation.

30 Jun 2012

Rate of small bowel biopsy is low in the U.S.

30 Jun 2012

Medivir, Bristol-Myers Squibb to initiate TMC435 and daclatasvir phase II combination study in HCV

Medivir AB, the research-based pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that a phase II combination study with the investigational compound TMC435 and Bristol-Myers Squibb's investigational compound daclatasvir will start in July.

29 Jun 2012

AASLD, EASL to hold special conference on therapy of HCV

The European Association for the Study of the Liver (EASL), together with the American Association for the Study of Liver Diseases (AASLD), will be holding an exciting "Special Conference" dedicated to the timely topic of: Therapy of Hepatitis C: Clinical Application and Drug Development.

29 Jun 2012